GB:0QAV Stock Latest News
PremiumThe FlyNanobiotix price target lowered to $8 from $12 at Guggenheim Nanobiotix’s Promising Future: Buy Rating Backed by Data-Rich 2025 and Strategic Advancements Nanobiotix: Strategic Partnerships and Clinical Advancements Drive Buy Rating PremiumThe FlyNanobiotix amends global licensing agreement with Janssen Pharmaceutica Nanobiotix files $200M mixed securities shelf Nanobiotix files to sell 5.62M ordinary shares for holders PremiumThe FlyNanobiotix initiated with a Buy at Guggenheim Nanobiotix initiated with a Buy at Stifel Nanobiotix announces new data from Study 1100